Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16398336,maximum levels,"Cortisol peaked at 20 min after administration of CRH in both cycling gilts and castrated boars with maximum levels of 149.3 +/- 16.5 nmol/l and 138.3 +/- 10.1 nmol/l, respectively.",Effect of ACTH and CRH on plasma levels of cortisol and prostaglandin F2alpha metabolite in cycling gilts and castrated boars. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16398336/),[nM] / [l],149.3,1623,DB01284,Cosyntropin
,16398336,maximum levels,"Cortisol peaked at 20 min after administration of CRH in both cycling gilts and castrated boars with maximum levels of 149.3 +/- 16.5 nmol/l and 138.3 +/- 10.1 nmol/l, respectively.",Effect of ACTH and CRH on plasma levels of cortisol and prostaglandin F2alpha metabolite in cycling gilts and castrated boars. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16398336/),[nM] / [l],138.3,1624,DB01284,Cosyntropin
,12008748,peak,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [ml],13.76,36625,DB01284,Cosyntropin
,12008748,peak,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [ml],4.77,36626,DB01284,Cosyntropin
,12008748,area under the curve,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [h·ml],190,36627,DB01284,Cosyntropin
,12008748,area under the curve,"However, the increment in plasma 17-OHP in patients both in terms of peak [13.76 +/- 2.52, 4.77 +/- 0.30ng/ml, mean +/- S.E.M, p < 0.001] and area under the curve [190 +/- 46, 96.75 +/- 32 ng/ml/h, p < 0.001] were significantly higher than that of the controls.",Twenty-four hour 17-hydroxyprogesterone response to adrenocorticotropine in adrenal incidentalomas: augmented response after adrenalectomy in two patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008748/),[ng] / [h·ml],96.75,36628,DB01284,Cosyntropin
,31251549,maximum plasma concentrations,"At steady-state, plasma concentrations increased ~1.8 to 2.1 fold versus first dose with mean (coefficient of variation [CV] %) maximum plasma concentrations of 4.4 ng/mL (67%) and 4.6 ng/mL (103%) in Cohort 1 and Cohort 2, respectively.","Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251549/),[ng] / [ml],4.4,70009,DB01284,Cosyntropin
,31251549,maximum plasma concentrations,"At steady-state, plasma concentrations increased ~1.8 to 2.1 fold versus first dose with mean (coefficient of variation [CV] %) maximum plasma concentrations of 4.4 ng/mL (67%) and 4.6 ng/mL (103%) in Cohort 1 and Cohort 2, respectively.","Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31251549/),[ng] / [ml],4.6,70010,DB01284,Cosyntropin
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],100.3,95830,DB01284,Cosyntropin
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],181.0,95831,DB01284,Cosyntropin
,8165188,bioavailability,Nasal bioavailability was low (4.4%) compared to i.m. (24%).,Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,4.4,123390,DB01284,Cosyntropin
,8165188,bioavailability,Nasal bioavailability was low (4.4%) compared to i.m. (24%).,Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,24,123391,DB01284,Cosyntropin
,8165188,bioavailability,Poloxamer 407 addition did not improve drug kinetics profiles and showed a non-significant decrease in bioavailability (4%).,Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,4,123392,DB01284,Cosyntropin
,8165188,Tmax,"The sodium glycocholate effect was very fast (Tmax = 5 min), but did not last long.",Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),min,5,123393,DB01284,Cosyntropin
,8165188,bioavailability,"On the other hand, maximum tetracosactide levels in plasma were reached after 15 min for the formulation containing bacitracin as enhancer, and tetracosactide bioavailability was strongly increased, to 24%, i.e., as much as after an i.m. injection.",Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165188/),%,24,123394,DB01284,Cosyntropin
,16918954,MRTs,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,0.14,133997,DB01284,Cosyntropin
,16918954,MRTs,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,0.37,133998,DB01284,Cosyntropin
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),[nM] / [l],1144,133999,DB01284,Cosyntropin
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),[nM] / [l],960,134000,DB01284,Cosyntropin
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,75,134001,DB01284,Cosyntropin
,16918954,maximum concentration (Cmax,"Elimination of ACTH(1-24) was faster in HDT than in LDT (MRTs of 0.14 vs 0.37, respectively, P = 0.008), but plasma concentrations were higher up to 60 min cortisol production in HDT reaching a higher maximum concentration (Cmax: 1144 vs 960 nmol/l) but delayed in time (75 vs 52.5 min).","Profile, mean residence time of ACTH and cortisol responses after low and standard ACTH tests in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918954/),,52.5,134002,DB01284,Cosyntropin
,28806969,AUC0-inf,"Based on the plasma pharmacokinetics and urinary profiles, 20β-dihydroprednisolone was confirmed as the main prednisolone-derived metabolite, being detected in the biological fluids of all 12 bovines (plasma AUC0-inf of 121 h μg L-1 and urinary concentration > 0.695 μg L-1).",Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28806969/),[h·μg] / [l],121,203536,DB01284,Cosyntropin
,32593173,bioavailability,The bioavailability of Nasacthin003 was 14.3%.,Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),%,14.3,204915,DB01284,Cosyntropin
,32593173,repeatability coefficient,"The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.",Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),[nM] / [l],105,204916,DB01284,Cosyntropin
,32593173,repeatability coefficient,"The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.",Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),[nM] / [l],10.3,204917,DB01284,Cosyntropin
,32593173,repeatability coefficient,"The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.",Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),[nM] / [l],21.1,204918,DB01284,Cosyntropin
,2170254,apparent clearance,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [h·kg],0.281,227308,DB01284,Cosyntropin
,2170254,apparent clearance,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [h·kg],0.455,227309,DB01284,Cosyntropin
,2170254,apparent volume of distribution,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [kg],0.520,227310,DB01284,Cosyntropin
,2170254,apparent volume of distribution,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [kg],1.28,227311,DB01284,Cosyntropin
,2170254,half-life,CAF half-life was lower in H(-) rats than in controls: 1.33 +/- 0.621 vs 2.12 +/- 0.676 h (-37%; P less than 0.01).,Effect of hypophysectomy on caffeine elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),h,1.33,227312,DB01284,Cosyntropin
,2170254,half-life,CAF half-life was lower in H(-) rats than in controls: 1.33 +/- 0.621 vs 2.12 +/- 0.676 h (-37%; P less than 0.01).,Effect of hypophysectomy on caffeine elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),h,2.12,227313,DB01284,Cosyntropin
